A big list of tiny biotech stocks with "explosive" potential catalysts

From The Life Sciences Report:

In January, The Life Sciences Report debuted its biotech watchlist, which outlined ideas for investors keyed to catalysts in the drug development process that typically move biotechnology stocks. All stocks are affected by catalysts, but nowhere do they provide more leverage (or deleverage) than in biotech. We predicted the new year would present legitimate prospects for portfolio growth. So far, that has been the case. Although the party has given way to some fatigue, the punch bowl is still on the table and the biotech upswing continues.

Back in January, our friends and collaborators at San Diego-based Sagient Research, publishers of the BioMedTracker, offered important information about market-moving data and events that can make or break smaller companies. In addition, a group of key biotech analysts weighed in on their best ideas -- 17 stocks in all. It was the perfect storm of individual ideas combined with a biotech wind from 2012 still billowing the sails.

As of April 22, the Nasdaq Biotechnology (NBI) index is up 26.6%. Have the biotech companies that made inaugural Biotech Watchlist -- and their stocks -- met the targets identified in the first quarter of 2013? Are there new catalysts? Check out the progress in the updated April biotech watchlist..(more).


Please share this article